Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.

International journal of cardiology·2026
Same author

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same author

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same author

Integrating Cardiopulmonary Exercise Testing, Stress Echocardiography and Near-Infrared Spectroscopy for Multimodal Assessment of Exercise Intolerance: A Narrative Review.

Healthcare (Basel, Switzerland)·2026
Same author

Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

[Gender bias and artificial intelligence in cardiology: evidence, clinical implications, and future perspectives].

Giornale italiano di cardiologia (2006)·2026

Related Experiment Video

Updated: May 11, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

The hemorrhagic risk: how to evaluate it.

Stefania Angela Di Fusco1, Furio Colivicchi, Massimo Santini

  • 1Cardiovascular Department, San Filippo Neri Hospital, Roma, Italy.

Pacing and Clinical Electrophysiology : PACE
|May 14, 2013
PubMed
Summary

Evaluating bleeding risk in atrial fibrillation patients on antithrombotic therapy is crucial. The HAS-BLED score helps estimate individual risk for better anticoagulation management.

Keywords:
atrial fibrillationbleeding riskoral anticoagulation

More Related Videos

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats
08:14

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats

Published on: March 22, 2024

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs
07:51

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs

Published on: May 21, 2019

Related Experiment Videos

Last Updated: May 11, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats
08:14

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats

Published on: March 22, 2024

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs
07:51

Standardized Hemorrhagic Shock Induction Guided by Cerebral Oximetry and Extended Hemodynamic Monitoring in Pigs

Published on: May 21, 2019

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Antithrombotic therapy is essential for atrial fibrillation (AF) patients to prevent stroke.
  • Bleeding complications are a significant concern in anticoagulation management.
  • Both traditional and novel oral anticoagulants pose bleeding risks.

Discussion:

  • Factors influencing bleeding risk in AF patients are reviewed.
  • The importance of assessing bleeding risk alongside thrombotic risk is highlighted.
  • Individualized risk assessment is key for safe and effective anticoagulation.

Key Insights:

  • The HAS-BLED score is a validated tool for estimating bleeding risk in AF patients.
  • International guidelines recommend the use of the HAS-BLED score.
  • Understanding and managing bleeding risk improves patient outcomes.

Outlook:

  • Further research may refine bleeding risk assessment tools.
  • Optimizing anticoagulation strategies to minimize bleeding is an ongoing challenge.
  • Improved patient selection and monitoring can enhance safety in antithrombotic treatment.